Please provide your email address to receive an email when new articles are posted on . Patients with migraine who switched from Aimovig to Emgality to treat their headaches reported similar ...

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. But they just made an exception for one of those companies: ...

Eli Lilly's Emgality didn't just hit the next-generation migraine market in third place behind Amgen and Novartis' Aimovig and Teva's Ajovy. It's been trailing its CGRP rivals in early sales results, ...

INDIANAPOLIS, May 10 (Reuters) - Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs ...

Last May, the Food and Drug Administration (FDA) approved Amgen and Novartis’ Aimovig, the first drug specifically designed to prevent chronic migraines, and offered new hope to the millions of ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. INDIANAPOLIS, Ind. – For the millions who ...

EXTON, Pa., Sept. 23, 2021 /PRNewswire/ — Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli Lilly announced initiation of a ...

The FDA just approved a new preventative migraine medication made by drug giant Eli Lilly. The drug, Emgality, is the third in a competitive new class of medication going after the 38 million ...